Cargando…
Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study
INTRODUCTION: The BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) vaccines have been approved for children and adolescents for protecting against SARS-CoV-2 infection. This longitudinal study aimed to compare adverse outcomes after SARS-CoV-2 vaccination in children with neurodevelopmental disord...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225977/ https://www.ncbi.nlm.nih.gov/pubmed/37271705 http://dx.doi.org/10.1016/j.vaccine.2023.05.067 |
_version_ | 1785050489751076864 |
---|---|
author | Wang, Liang-Jen Tsai, Ching-Shu Chou, Wen-Jiun Li, Chia-Jung Lee, Sheng-Yu Chen, Yi-Chun Lin, I-Chun |
author_facet | Wang, Liang-Jen Tsai, Ching-Shu Chou, Wen-Jiun Li, Chia-Jung Lee, Sheng-Yu Chen, Yi-Chun Lin, I-Chun |
author_sort | Wang, Liang-Jen |
collection | PubMed |
description | INTRODUCTION: The BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) vaccines have been approved for children and adolescents for protecting against SARS-CoV-2 infection. This longitudinal study aimed to compare adverse outcomes after SARS-CoV-2 vaccination in children with neurodevelopmental disorders (ND) (e.g., attention-deficit/hyperactivity disorder [ADHD], autism spectrum disorder [ASD], communication disorders, intellectual disability, and tic disorders) and healthy control children. METHODS: A total of 1335 children who received the SARS-CoV-2 vaccination (762 children with ND and 573 healthy controls) were recruited. All subjects were followed-up for 180 days, and outcome events were defined as outpatient department (OPD) or emergency department (ER) visits during follow-up. Multivariate Cox proportional hazards regression models were used to identify the potential differences in outcomes between the propensity score-matched ND group (n = 311) and the control group (n = 311), and to explore the factors associated with outcomes among all children with ND (n = 762). RESULTS: Compared with the control group, children with ND exhibited a higher likelihood of subsequent OPD or ER visits and paediatric neurology OPD visits after the first dose of vaccination. However, we found that only a small proportion of the children visited the OPD or ER because of adverse vaccination-related effects. Among all children with ND, those with communication disorders showed a higher likelihood of any OPD or ER visit. Paediatric neurology OPD visits were associated with communication disorders, intellectual disability, and methylphenidate and aripiprazole prescriptions. ADHD and ASD were not associated with adverse outcomes. CONCLUSIONS: No specific ND diagnosis or medication use clearly increased the risk of adverse effects of SARS-CoV-2 vaccination. Children with ND can be reassured that the SARS-CoV-2 vaccination is a safe regimen to protect themselves. |
format | Online Article Text |
id | pubmed-10225977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102259772023-05-30 Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study Wang, Liang-Jen Tsai, Ching-Shu Chou, Wen-Jiun Li, Chia-Jung Lee, Sheng-Yu Chen, Yi-Chun Lin, I-Chun Vaccine Article INTRODUCTION: The BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) vaccines have been approved for children and adolescents for protecting against SARS-CoV-2 infection. This longitudinal study aimed to compare adverse outcomes after SARS-CoV-2 vaccination in children with neurodevelopmental disorders (ND) (e.g., attention-deficit/hyperactivity disorder [ADHD], autism spectrum disorder [ASD], communication disorders, intellectual disability, and tic disorders) and healthy control children. METHODS: A total of 1335 children who received the SARS-CoV-2 vaccination (762 children with ND and 573 healthy controls) were recruited. All subjects were followed-up for 180 days, and outcome events were defined as outpatient department (OPD) or emergency department (ER) visits during follow-up. Multivariate Cox proportional hazards regression models were used to identify the potential differences in outcomes between the propensity score-matched ND group (n = 311) and the control group (n = 311), and to explore the factors associated with outcomes among all children with ND (n = 762). RESULTS: Compared with the control group, children with ND exhibited a higher likelihood of subsequent OPD or ER visits and paediatric neurology OPD visits after the first dose of vaccination. However, we found that only a small proportion of the children visited the OPD or ER because of adverse vaccination-related effects. Among all children with ND, those with communication disorders showed a higher likelihood of any OPD or ER visit. Paediatric neurology OPD visits were associated with communication disorders, intellectual disability, and methylphenidate and aripiprazole prescriptions. ADHD and ASD were not associated with adverse outcomes. CONCLUSIONS: No specific ND diagnosis or medication use clearly increased the risk of adverse effects of SARS-CoV-2 vaccination. Children with ND can be reassured that the SARS-CoV-2 vaccination is a safe regimen to protect themselves. Elsevier Ltd. 2023-06-29 2023-05-29 /pmc/articles/PMC10225977/ /pubmed/37271705 http://dx.doi.org/10.1016/j.vaccine.2023.05.067 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Wang, Liang-Jen Tsai, Ching-Shu Chou, Wen-Jiun Li, Chia-Jung Lee, Sheng-Yu Chen, Yi-Chun Lin, I-Chun Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study |
title | Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study |
title_full | Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study |
title_fullStr | Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study |
title_full_unstemmed | Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study |
title_short | Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study |
title_sort | medical outcomes of children with neurodevelopmental disorders after sars-cov-2 vaccination: a six-month follow-up study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225977/ https://www.ncbi.nlm.nih.gov/pubmed/37271705 http://dx.doi.org/10.1016/j.vaccine.2023.05.067 |
work_keys_str_mv | AT wangliangjen medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy AT tsaichingshu medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy AT chouwenjiun medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy AT lichiajung medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy AT leeshengyu medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy AT chenyichun medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy AT linichun medicaloutcomesofchildrenwithneurodevelopmentaldisordersaftersarscov2vaccinationasixmonthfollowupstudy |